JP2025501765A - 二官能性スルホンアミド化合物 - Google Patents

二官能性スルホンアミド化合物 Download PDF

Info

Publication number
JP2025501765A
JP2025501765A JP2024538381A JP2024538381A JP2025501765A JP 2025501765 A JP2025501765 A JP 2025501765A JP 2024538381 A JP2024538381 A JP 2024538381A JP 2024538381 A JP2024538381 A JP 2024538381A JP 2025501765 A JP2025501765 A JP 2025501765A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
mmol
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501765A5 (https=
Inventor
ブジョゾフスキ,マーティン
ガルニエ,ジャン-マルク・ダニエル
ガードナー,クリストファー
レッセン,ギヨーム・ローラント
ケルステン,ビルヘルムス・ヨハネス・アントニウス
Original Assignee
アナシス・ファルマ・プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904204A external-priority patent/AU2021904204A0/en
Application filed by アナシス・ファルマ・プロプライエタリー・リミテッド filed Critical アナシス・ファルマ・プロプライエタリー・リミテッド
Publication of JP2025501765A publication Critical patent/JP2025501765A/ja
Publication of JP2025501765A5 publication Critical patent/JP2025501765A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024538381A 2021-12-22 2022-12-22 二官能性スルホンアミド化合物 Pending JP2025501765A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021904204A AU2021904204A0 (en) 2021-12-22 Bifunctional sulphonamide compounds
AU2021904204 2021-12-22
PCT/AU2022/051575 WO2023115149A1 (en) 2021-12-22 2022-12-22 Bifunctional sulphonamide compounds

Publications (2)

Publication Number Publication Date
JP2025501765A true JP2025501765A (ja) 2025-01-23
JP2025501765A5 JP2025501765A5 (https=) 2025-12-19

Family

ID=86900865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538381A Pending JP2025501765A (ja) 2021-12-22 2022-12-22 二官能性スルホンアミド化合物

Country Status (9)

Country Link
US (1) US20250074891A1 (https=)
EP (1) EP4452966A4 (https=)
JP (1) JP2025501765A (https=)
KR (1) KR20240151737A (https=)
CN (1) CN119013268A (https=)
AU (1) AU2022420983A1 (https=)
CA (1) CA3241593A1 (https=)
MX (1) MX2024007883A (https=)
WO (1) WO2023115149A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy
WO2025155642A1 (en) * 2024-01-21 2025-07-24 The Regents Of The University Of California Dcaf16-based covalent handle for the rational design of monovalent degraders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948544A1 (en) * 2014-05-15 2015-11-19 Catalyst Therapeutics Pty Ltd Methods for inhibiting necroptosis
CA2976121A1 (en) * 2015-02-10 2016-08-18 Catalyst Therapeutics Pty Ltd Inhibitors of necroptosis
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
DK4168401T3 (da) * 2020-06-19 2026-04-13 Anaxis Pharma Pty Ltd Sulfonamidforbindelser

Also Published As

Publication number Publication date
US20250074891A1 (en) 2025-03-06
WO2023115149A1 (en) 2023-06-29
CA3241593A1 (en) 2023-06-29
CN119013268A (zh) 2024-11-22
AU2022420983A1 (en) 2024-07-04
EP4452966A4 (en) 2025-12-17
EP4452966A1 (en) 2024-10-30
KR20240151737A (ko) 2024-10-18
MX2024007883A (es) 2024-09-23

Similar Documents

Publication Publication Date Title
JP5524171B2 (ja) キナーゼ阻害剤
JP7769648B2 (ja) スルホンアミド化合物
AU2022349569A1 (en) Pyridine derivative and use thereof
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
WO2006080450A1 (ja) Igf-1r阻害剤
TW201734015A (zh) 1,5-萘啶衍生物與含此之melk抑制劑
JP2025501766A (ja) 二官能性アリールスルホンアミド化合物
JP2025501765A (ja) 二官能性スルホンアミド化合物
JP2024502178A (ja) Sgk-1を阻害するためのピラゾロ[3,4-d]ピリミジン-6-イル-スルホンアミド誘導体
JPWO2019189555A1 (ja) 複素環化合物
JP2020506172A (ja) 化合物及び住血吸虫症の治療におけるそれらの使用
EP4452977A1 (en) Arylsulphonamide compounds
AU2021290652A1 (en) Amido compounds
KR20200032002A (ko) 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염
OA21863A (en) Indazole based compounds and associated methods of use.
HK40048972A (en) Inhibitors of cyclin-dependent kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251211